Flucas Ventures — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
EnClear Therapiesencleartherapies.cominFeb 2024
EnClear Therapies develops precision drug delivery technology targeting the central nervous system for patients with CNS diseases including neuro-oncology, neurodegenerative disorders, and autoimmune conditions.
BiotechDigital HealthMedical DevicesCambridge, US
Jonathan Fleming(Director)Jason Camm(Director)Kasper Roet(Director)Anthony DePasqua(Executive Officer, Director)
PartnerAshley Flucas· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.